Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Conley, R. R. Articles by Zaremba, S. Search for Related Content PubMed Citation Articles by Conley, R. R. Articles by Zaremba, S.

Olanzapine Compared With Chlorpromazine in Treatment-Resistant Schizophrenia

OBJECTIVE: The purpose of this study was to compare the efficacy of olanzapine with that of chlorpromazine plus benztropine in patients with treatment-resistant schizophrenia. METHOD: One hundred three previously treatment-resistant patients with schizophrenia diagnosed according to the DSM-III-R criteria were given a prospective 6-week trial of 10–40 mg/day of haloperidol. Eighty-four of them failed to respond to that trial and agreed to be randomly assigned to an 8-week fixed-dose trial of either 25 mg/day of olanzapine alone or 1200 mg/day of chlorpromazine plus 4 mg/day of benztropine mesylate. RESULTS: Fifty-nine (70%) of the 84 subjects completed the trial. The primary outcome measures were Brief Psychiatric Rating Scale total score and positive symptom score, Scale for the Assessment of Negative Symptoms global score, and Clinical Global Impression score. An analysis of variance for the subjects who completed the study showed no difference in efficacy between the two drugs. Seven percent of the olanzapine-treated patients responded according to a priori criteria; no chlorpromazine-treated patients responded. The olanzapine-treated patients had fewer motor and cardiovascular side effects than the chlorpromazine-treated patients. Extrapyramidal symptoms and akathisia were similar in the two groups, although no antiparkinsonian drugs were used in the olanzapine group. CONCLUSIONS: Olanzapine and chlorpromazine showed similar efficacy, and the total amount of improvement with either drug was modest. Olanzapine-treated patients had fewer side effects than chlorpromazine-treated patients. (Am J Psychiatry 1998; 155:914–920)

This article has been cited by other articles:

				J. Rabinowitz and O. Davidov A Composite Approach That Includes Dropout Rates When Analyzing Efficacy Data in Clinical Trials of Antipsychotic Medications Schizophr Bull, November 1, 2008; 34(6): 1145 - 1150. [Abstract] [Full Text] [PDF]

				J. Rabinowitz, S. Z. Levine, O. Barkai, and O. Davidov Dropout Rates in Randomized Clinical Trials of Antipsychotics: A Meta-analysis Comparing First- and Second-Generation Drugs and an Examination of the Role of Trial Design Features Schizophr Bull, February 26, 2008; (2008) sbn005v1. [Abstract] [Full Text] [PDF]

				J. Kreyenbuhl, S. C. Marcus, J. C. West, J. Wilk, and M. Olfson Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia Focus, January 1, 2008; 6(2): 212 - 220. [Abstract] [Full Text] [PDF]

				J. Kreyenbuhl, S. C. Marcus, J. C. West, J. Wilk, and M. Olfson Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia Psychiatr Serv, July 1, 2007; 58(7): 983 - 990. [Abstract] [Full Text] [PDF]

				R. Ganguli and M. Strassnig Are older antipsychotic drugs obsolete? BMJ, June 10, 2006; 332(7554): 1346 - 1347. [Full Text] [PDF]

				R. W. Kerwin and A. Bolonna Management of clozapine-resistant schizophrenia Advan. Psychiatr. Treat., March 1, 2005; 11(2): 101 - 106. [Abstract] [Full Text] [PDF]

				R. A. Rosenheck Open Forum: Effectiveness Versus Efficacy of Second-Generation Antipsychotics: Haloperidol Without Anticholinergics as a Comparator Psychiatr Serv, January 1, 2005; 56(1): 85 - 92. [Full Text] [PDF]

				R. W. Buchanan, M. P. Ball, E. Weiner, B. Kirkpatrick, J. M. Gold, R. P. McMahon, and W. T. Carpenter Jr. Olanzapine Treatment of Residual Positive and Negative Symptoms Am J Psychiatry, January 1, 2005; 162(1): 124 - 129. [Abstract] [Full Text] [PDF]

				J. Volavka, P. Czobor, B. Sheitman, J.-P. Lindenmayer, L. Citrome, J. P. McEvoy, T. B. Cooper, M. Chakos, and J. A. Lieberman Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder Focus, January 1, 2004; 2(1): 59 - 67. [Abstract] [Full Text] [PDF]

				M. Chakos, J. Lieberman, E. Hoffman, D. Bradford, and B. Sheitman Effectiveness of Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: A Review and Meta-Analysis of Randomized Trials Focus, January 1, 2004; 2(1): 111 - 121. [Abstract] [Full Text] [PDF]

				R. Rosenheck, D. Perlick, S. Bingham, W. Liu-Mares, J. Collins, S. Warren, D. Leslie, E. Allan, E. C. Campbell, S. Caroff, et al. Effectiveness and Cost of Olanzapine and Haloperidol in the Treatment of Schizophrenia: A Randomized Controlled Trial JAMA, November 26, 2003; 290(20): 2693 - 2702. [Abstract] [Full Text] [PDF]

				J. M. Davis, N. Chen, and I. D. Glick A Meta-analysis of the Efficacy of Second-Generation Antipsychotics Arch Gen Psychiatry, June 1, 2003; 60(6): 553 - 564. [Abstract] [Full Text] [PDF]

				H. S. Dinakar, R. N. Sobel, J. H. Bopp, A. Daniels, and S. Mauro Efficacy of Olanzapine and Risperidone for Treatment-Refractory Schizophrenia Among Long-Stay State Hospital Patients Psychiatr Serv, June 1, 2002; 53(6): 755 - 757. [Abstract] [Full Text] [PDF]

				S. Leucht, G. Pitschel-Walz, R. R. Engel, and W. Kissling Amisulpride, an Unusual ""Atypical"" Antipsychotic: A Meta-Analysis of Randomized Controlled Trials Am J Psychiatry, February 1, 2002; 159(2): 180 - 190. [Abstract] [Full Text] [PDF]

				J. Volavka, P. Czobor, B. Sheitman, J.-P. Lindenmayer, L. Citrome, J. P. McEvoy, T. B. Cooper, M. Chakos, and J. A. Lieberman Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder Am J Psychiatry, February 1, 2002; 159(2): 255 - 262. [Abstract] [Full Text] [PDF]

				C. Prior, J. Clements, M. Rowett, D. Taylor, R. Rowsell, C. Link, J. Donoghue, S. Lee, I. Anderson, R. Duggins, et al. Atypical antipsychotics in the treatment of schizophrenia BMJ, April 14, 2001; 322(7291): 924a - 924. [Full Text]

				M. Chakos, J. Lieberman, E. Hoffman, D. Bradford, and B. Sheitman Effectiveness of Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: A Review and Meta-Analysis of Randomized Trials Am J Psychiatry, April 1, 2001; 158(4): 518 - 526. [Abstract] [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 1998 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us